Machine-learning metabolomics prioritizes succinate in sepsis-associated encephalopathy
Source check: Source checked. Not independent scientific confirmation.
Finding: In plasma samples from 29 controls, 32 sepsis patients and 27 patients with sepsis-associated encephalopathy (SAE), LC–MS/MS plus machine-learning feature selection identified a 12-metabolite profile. Succinate rose stepwise from controls to sepsis to SAE, ranked among the five leading XGBoost features, and correlated with APACHE II, SOFA and lactate. In a cecal-ligation-and-puncture mouse model, dietary succinate supplementation before sepsis worsened cognitive-test performance, neuronal injury and microglial activation; succinate also increased inflammatory gene expression in cultured microglia.
Technology: Random forest and support-vector-machine feature ranking with XGBoost classification
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning feature selection and classifier comparison were applied to the measured plasma metabolomics to identify discriminatory features; succinate ranked among the top five XGBoost features. Researchers then tested its functional relevance through supplementation in a mouse sepsis model and in cultured microglia. The animal/cell experiments were human-directed follow-up, not model-generated predictions.
- Test and result
- In a cecal-ligation-and-puncture mouse model, dietary succinate supplementation before sepsis worsened cognitive-test performance, neuronal injury and microglial activation; succinate also increased inflammatory gene expression in cultured microglia.
- Limitation / still unknown
- The human discovery cohort comprised 88 participants and the held-out model test set had 18 participants, so diagnostic performance and metabolite ranking need larger external cohorts. Succinate supplementation was given before CLP in mice, and cell experiments used a microglial cell line; these are preclinical perturbations and do not prove that succinate causes human SAE or that targeting it improves patient outcomes. Associations with severity scores are observational.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12809278/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.